Charles J, Vrionis A, Mansur A, Mathias T, Shaikh J, Ciner A
Cancers (Basel). 2023; 15(9).
PMID: 37174089
PMC: 10177356.
DOI: 10.3390/cancers15092624.
Bowakim-Anta N, Acolty V, Azouz A, Yagita H, Leo O, Goriely S
Front Immunol. 2023; 14:1023064.
PMID: 36993956
PMC: 10041113.
DOI: 10.3389/fimmu.2023.1023064.
Yoo S, Lee H, Kim J, Yoo I, Park C, Kang S
Int J Mol Sci. 2022; 23(4).
PMID: 35216458
PMC: 8877612.
DOI: 10.3390/ijms23042342.
Singh K, Hotchkiss K, Mohan A, Reedy J, Sampson J, Khasraw M
J Immunother Cancer. 2021; 9(11).
PMID: 34795007
PMC: 8603282.
DOI: 10.1136/jitc-2021-003679.
Singh K, Hotchkiss K, Patel K, Wilkinson D, Mohan A, Cook S
Cancers (Basel). 2021; 13(21).
PMID: 34771532
PMC: 8582389.
DOI: 10.3390/cancers13215367.
Conditioning treatment with CD27 Ab enhances expansion and antitumor activity of adoptively transferred T cells in mice.
Wasiuk A, Weidlick J, Sisson C, Widger J, Crocker A, Vitale L
Cancer Immunol Immunother. 2021; 71(1):97-109.
PMID: 34028568
PMC: 8739312.
DOI: 10.1007/s00262-021-02958-9.
Activation of OX40 and CD27 Costimulatory Signalling in Sheep through Recombinant Ovine Ligands.
Rojas J, Alejo A, Avia J, Rodriguez-Martin D, Sanchez C, Alcami A
Vaccines (Basel). 2020; 8(2).
PMID: 32580486
PMC: 7350415.
DOI: 10.3390/vaccines8020333.
Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.
ONeill R, Cao X
Adv Cancer Res. 2019; 143:145-194.
PMID: 31202358
PMC: 7336166.
DOI: 10.1016/bs.acr.2019.03.003.
CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy.
Wasiuk A, Testa J, Weidlick J, Sisson C, Vitale L, Widger J
J Immunol. 2017; 199(12):4110-4123.
PMID: 29109120
PMC: 5713498.
DOI: 10.4049/jimmunol.1700606.
Crystal structure of CD27 in complex with a neutralizing noncompeting antibody.
Teplyakov A, Obmolova G, Malia T, Gilliland G
Acta Crystallogr F Struct Biol Commun. 2017; 73(Pt 5):294-299.
PMID: 28471362
PMC: 5417320.
DOI: 10.1107/S2053230X17005957.
Human immunity against EBV-lessons from the clinic.
Tangye S, Palendira U, Edwards E
J Exp Med. 2017; 214(2):269-283.
PMID: 28108590
PMC: 5294862.
DOI: 10.1084/jem.20161846.
Combined immunodeficiency and Epstein-Barr virus-induced B cell malignancy in humans with inherited CD70 deficiency.
Abolhassani H, Edwards E, Ikinciogullari A, Jing H, Borte S, Buggert M
J Exp Med. 2016; 214(1):91-106.
PMID: 28011864
PMC: 5206499.
DOI: 10.1084/jem.20160849.
CD70 and IFN-1 selectively induce eomesodermin or T-bet and synergize to promote CD8+ T-cell responses.
Dong H, Franklin N, Ritchea S, Yagita H, Glennie M, Bullock T
Eur J Immunol. 2015; 45(12):3289-301.
PMID: 26461455
PMC: 4752831.
DOI: 10.1002/eji.201445291.
Evolving synergistic combinations of targeted immunotherapies to combat cancer.
Melero I, Berman D, Aznar M, Korman A, Perez Gracia J, Haanen J
Nat Rev Cancer. 2015; 15(8):457-72.
PMID: 26205340
DOI: 10.1038/nrc3973.
T cells compete by cleaving cell surface CD27 and blocking access to CD70-bearing APCs.
Burchill M, Tamburini B, Kedl R
Eur J Immunol. 2015; 45(11):3140-9.
PMID: 26179759
PMC: 4674305.
DOI: 10.1002/eji.201545749.
CD70 is downregulated by interaction with CD27.
Kuka M, Munitic I, Giardino Torchia M, Ashwell J
J Immunol. 2013; 191(5):2282-9.
PMID: 23913967
PMC: 3750068.
DOI: 10.4049/jimmunol.1300868.
Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity.
Huang J, Jochems C, Anderson A, Talaie T, Jales A, Madan R
J Immunol. 2013; 190(12):6250-8.
PMID: 23677477
PMC: 4084782.
DOI: 10.4049/jimmunol.1300022.
CD70 deficiency impairs effector CD8 T cell generation and viral clearance but is dispensable for the recall response to lymphocytic choriomeningitis virus.
Munitic I, Kuka M, Allam A, Scoville J, Ashwell J
J Immunol. 2012; 190(3):1169-79.
PMID: 23269247
PMC: 3552005.
DOI: 10.4049/jimmunol.1202353.
CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia.
van Montfrans J, Hoepelman A, Otto S, van Gijn M, van de Corput L, de Weger R
J Allergy Clin Immunol. 2011; 129(3):787-793.e6.
PMID: 22197273
PMC: 3294016.
DOI: 10.1016/j.jaci.2011.11.013.
Tumor necrosis factor receptor/tumor necrosis factor family members in antiviral CD8 T-cell immunity.
Salek-Ardakani S, Croft M
J Interferon Cytokine Res. 2010; 30(4):205-18.
PMID: 20377415
PMC: 3001890.
DOI: 10.1089/jir.2010.0026.